AU2022212119A1 - Compositions and methods for the treatment of graft versus host disease - Google Patents

Compositions and methods for the treatment of graft versus host disease Download PDF

Info

Publication number
AU2022212119A1
AU2022212119A1 AU2022212119A AU2022212119A AU2022212119A1 AU 2022212119 A1 AU2022212119 A1 AU 2022212119A1 AU 2022212119 A AU2022212119 A AU 2022212119A AU 2022212119 A AU2022212119 A AU 2022212119A AU 2022212119 A1 AU2022212119 A1 AU 2022212119A1
Authority
AU
Australia
Prior art keywords
apraglutide
subject
administered
gvhd
transplant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022212119A
Other languages
English (en)
Other versions
AU2022212119A9 (en
Inventor
Violetta Dimitriadou
Nader N. YOUSSEF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectivbio AG
Original Assignee
Vectivbio AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectivbio AG filed Critical Vectivbio AG
Publication of AU2022212119A1 publication Critical patent/AU2022212119A1/en
Publication of AU2022212119A9 publication Critical patent/AU2022212119A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2022212119A 2021-01-28 2022-01-28 Compositions and methods for the treatment of graft versus host disease Pending AU2022212119A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163142905P 2021-01-28 2021-01-28
US63/142,905 2021-01-28
US202163248074P 2021-09-24 2021-09-24
US63/248,074 2021-09-24
PCT/US2022/014349 WO2022165204A1 (en) 2021-01-28 2022-01-28 Compositions and methods for the treatment of graft versus host disease

Publications (2)

Publication Number Publication Date
AU2022212119A1 true AU2022212119A1 (en) 2023-08-10
AU2022212119A9 AU2022212119A9 (en) 2024-05-16

Family

ID=80461100

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022212119A Pending AU2022212119A1 (en) 2021-01-28 2022-01-28 Compositions and methods for the treatment of graft versus host disease

Country Status (11)

Country Link
US (3) US20220233645A1 (https=)
EP (2) EP4635509A1 (https=)
JP (1) JP2024507324A (https=)
KR (1) KR20230167019A (https=)
AU (1) AU2022212119A1 (https=)
BR (1) BR112023014978A2 (https=)
CA (1) CA3206093A1 (https=)
ES (1) ES3044110T3 (https=)
IL (1) IL304675A (https=)
MX (1) MX2023008793A (https=)
WO (1) WO2022165204A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025208047A1 (en) * 2024-03-28 2025-10-02 Vectivbio Ag Glucagon-like peptide 2 (glp-2) analogs for the treatment of graft versus host disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8421271B2 (en) * 2009-08-31 2013-04-16 General Electric Company Apparatus for transferring energy using onboard power electronics and method of manufacturing same
EP2314616A1 (en) 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists
EP3924369A1 (en) * 2019-02-11 2021-12-22 OPKO Biologics Ltd. Long-acting glp-2 analogs
KR20230038187A (ko) 2020-06-09 2023-03-17 벡티브바이오 에이지 아프라글루타이드의 제조, 제형화 및 투여

Also Published As

Publication number Publication date
IL304675A (en) 2023-09-01
JP2024507324A (ja) 2024-02-19
ES3044110T3 (en) 2025-11-26
AU2022212119A9 (en) 2024-05-16
EP4635509A1 (en) 2025-10-22
BR112023014978A2 (pt) 2023-11-07
EP4284410A1 (en) 2023-12-06
CA3206093A1 (en) 2022-08-04
EP4284410B1 (en) 2025-07-02
WO2022165204A1 (en) 2022-08-04
US20240123036A1 (en) 2024-04-18
US20220233645A1 (en) 2022-07-28
US20240285730A1 (en) 2024-08-29
KR20230167019A (ko) 2023-12-07
MX2023008793A (es) 2024-02-15

Similar Documents

Publication Publication Date Title
JP7445893B2 (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
CN105722852B (zh) 用于治疗口腔粘膜炎的新型肽和类似物
US20240285730A1 (en) Compositions and methods for the treatment of graft versus host disease
US8435520B2 (en) Combinations of immunosuppressive agents for the treatment or prevention of graft rejections
Martin et al. Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host disease
MXPA05009741A (es) Tratamientos antitumorales mejorados.
CN117460523A (zh) 用于治疗移植物抗宿主病的组合物和方法
Traitanon et al. Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study
HK40102861B (en) Apraglutide for use in the treatment of gastrointestinal graft versus host disease
HK40102861A (en) Apraglutide for use in the treatment of gastrointestinal graft versus host disease
EA051756B1 (ru) Композиции и способы лечения болезни "трансплантат против хозяина"
WO2025208047A1 (en) Glucagon-like peptide 2 (glp-2) analogs for the treatment of graft versus host disease
Giralt et al. Studies of decitabine with allogeneic progenitor cell transplantation.
US10154989B2 (en) Methods of managing graft versus host disease (GvHD) using indole carboxyaldehydes or derivatives thereof
Suzuki et al. A new immunosuppressant, FTY720, in canine kidney transplantation: Effect of single‐drug, induction and combination treatments
Bakr et al. Optimizing immunosuppressive regimens among living-donor renal transplant recipients
Rummel German experience with bendamustine treating Relapsed/Refractory indolent B-Cell and mantle cell lymphomas
JP2006522060A5 (https=)
Bansal et al. Safety and efficacy of high dose melphalan and autologous stem cell transplantation prior to renal allograft in end-stage renal failure secondary to monoclonal immunoglobulin deposition disease
Han et al. Artesunate synergized dexamethasone in protecting intestinal barrier against acute graft-versus-host disease in a murine model
Raida et al. Allogeneic stem cell transplantation after fludarabine, melphalan and thymoglobulin followed by early withdrawal of prophylactic immunosuppression could be an effective approach to patients with acute lymphoblastic leukemia
Ołdakowska-Jedynak et al. Successful reversal of acute vascular rejection and cyclosporine-associated nephrotoxicity in renal allograft with combined sirolimus and mycophenolate mofetil as immunotherapy
CA3154497A1 (en) Combination therapy for treating a hematological malignancy
Martella et al. A pilot study of a day one and eight every three weeks administration of docetaxel in metastatic cancer patients
Vermeire et al. Do antibiotics have a role in Crohn's disease?

Legal Events

Date Code Title Description
SREP Specification republished